2026-06-08 - LD Brussels - 2seventy bio, Inc. v. Johnson & Johnson, Janssen (Biotech / Pharmaceuticals / Cilag entities) and Legend Biotech (Corporation / USA / Ireland / Belgium); intervener and patent proprietor: The United States of America (Department of Health and Human Services) - UPC-CFI-0001934/2026
- Aktenzeichen:
- UPC-CFI-0001934/2026
- Datum:
- Spruchkörper:
- Court of First Instance - Brussels (BE) Local Division
- Art:
- Order
- Parteien:
- 2seventy bio, Inc. v. Johnson & Johnson, Janssen (Biotech / Pharmaceuticals / Cilag entities) and Legend Biotech (Corporation / USA / Ireland / Belgium); intervener and patent proprietor: The United States of America (Department of Health and Human Services)
Kernaussage: In a procedural order under R.
2026-06-08 - LD Brussels - 2seventy bio, Inc. v. Johnson & Johnson, Janssen (Biotech / Pharmaceuticals / Cilag entities) and Legend Biotech (Corporation / USA / Ireland / Belgium); intervener and patent proprietor: The United States of America (Department of Health and Human Services) - UPC-CFI-0001934/2026
routine
In a procedural order under R. 37.2 RoP, the Brussels Local Division announced its intention to decide, before the close of the written procedure, how to proceed with the counterclaim for revocation under Art. 33(3) UPCA. The panel signalled that it intends to exercise its discretion under Art. 33(3)(a) UPCA to hear the infringement action (UPC_CFI_029/2026) together with the revocation counterclaims (UPC_CFI_1934/2026 and UPC_CFI_1940/2026), rather than referring revocation to the central division. It reasoned that a joint hearing serves procedural efficiency and ensures that validity and infringement are decided on a uniform interpretation of the patent by the same panel composed of the same judges. The parties were given until 12 June 2026 (18:00 CEST) to comment, with silence treated as agreement to a joint hearing. The order disposes of no case on the merits.